Discovery of YK-029A, a novel mutant EGFR inhibitor targeting both T790 M and exon 20 insertion mutations, as a treatment for NSCLC

Bin Liu, Feng Gao, Huijun Zhao, Shuai Yuan, Xingzhe Peng, Pengzhi Zhang, Jing Wang, Tongmei Zhang, Maosheng Duan, Yongqi Guo